Interleukin-5 antagonist
US6465616B1 · kind B1 · utility
1Cited by
0References
16Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Apr 12, 1999 |
| Grant date | Oct 15, 2002 |
| Priority date | — |
| Expiry date | Apr 12, 2019 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K38/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to modified and variant forms of Interleukin-5 molecules capable of antagonizing or reducing the activity of IL-5 and their use in ameliorating, abating or otherwise reducing the aberrant effects caused by native or mutant forms of IL-5.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.